Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hilleman CEO On Cost Gains From A Simpler Cholera Vaccine

Executive Summary

Hilleman Laboratories is confident that its oral cholera vaccine, with "multi-fold differentiation" can be manufactured at much lower costs than existing products such as Sanofi-owned Shantha Biotechnics Ltd.'s Shanchol and Valneva SE's Dukoral.

You may also be interested in...

Latecomer Hilleman Looks To Leverage Cholera Vaccine Advantages

Hilleman Laboratories' CEO believes the Indian venture’s oral cholera vaccine could become the best in its class, telling Scrip cost-effectiveness is critical amid growing budgetary strains and outlining plans for a convenient tablet form.

Valneva builds on traveler's vaccine franchise with €45m Dukoral buy

France's Valneva has cemented its position in the traveler's vaccine market, acquiring Crucell's cholera and traveler's diarrhea vaccine Dukoral for €45m.

Hilleman CEO on why new cholera vaccine could be 'high impact'

Hilleman Laboratories, the joint venture between Merck & Co and Wellcome Trust, and Gotovax AB, a University of Gothenburg spin-off biopharma firm, have outlined plans to develop a cut-price oral cholera vaccine that could potentially address some of the key limitations of existing products for the deadly disease.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts